Nymox Pharmaceutical Corporation (Bahamas) - ADR

factsheet Factsheet
  • Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $18 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-1 Mln

Nymox Pharmaceutical Corporation (Bahamas) - ADR Share Price

$0.47

As on 07-Sep-2023 09:30 EST

up-down-arrow $-0.06-11.77%

  • Prev Close info

    $0.53

  • Day's Openinfo

    $0.51

  • Today's Highinfo

    $0.51

  • Today's Lowinfo

    $0.47

  • Today's Volumeinfo

    8,769

  • 52 Week rangeinfo

    $0.12 - 1.15

Please wait...

Nymox Pharmaceutical Corporation (Bahamas) - ADR Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Nymox Pharmaceutical Corporation (Bahamas) - ADR
46.13 -53.24 14.05 16.90 -43.26 -29.05 -24.44
S&P BSE Sensex*
1.25 2.41 10.78 22.43 13.71 15.31 13.45
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 07-Sep-2023  |  *As on 23-Feb-2024  |  #As on 26-Oct-2023
2022
2021
2020
2019
2018
2017
2016
Nymox Pharmaceutical Corporation (Bahamas) - ADR
-75.38 -47.58 12.73 67.94 -60.10 23.60 -18.60
S&P Small-Cap 600
-17.42 25.27 9.57 20.86 -9.70 11.73 24.74
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Nymox Pharmaceutical Corporation (Bahamas) - ADR Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Nymox Pharmaceutical Corporation (Bahamas) - ADR

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Nymox Pharmaceutical Corporation (Bahamas) - ADR

        Founder, Chairman, CEO & Pres

        Dr. Paul Averback DABP, M.D.

        Gen. Counsel, Sec., COO & Director

        Mr. Randall J. Lanham Esq., J.D.

        Headquarters

        Nassau

        FAQs for Nymox Pharmaceutical Corporation (Bahamas) - ADR

        The total asset value of Nymox Pharmaceutical Corporation (Bahamas) - ADR stood at $ 3 Mln as on 30-Jun-23

        The share price of Nymox Pharmaceutical Corporation (Bahamas) - ADR is $0.47 (NASDAQ) as of 07-Sep-2023 09:30 EST. Nymox Pharmaceutical Corporation (Bahamas) - ADR has given a return of -43.26% in the last 3 years.

        Nymox Pharmaceutical Corporation (Bahamas) - ADR has a market capitalisation of $ 18 Mln as on 07-Sep-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Nymox Pharmaceutical Corporation (Bahamas) - ADR is 48.02 times as on 07-Sep-2023, a 16.53% premium to its peers’ median range of 2.74 times.

        Since, TTM earnings of Nymox Pharmaceutical Corporation (Bahamas) - ADR is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Nymox Pharmaceutical Corporation (Bahamas) - ADR and enter the required number of quantities and click on buy to purchase the shares of Nymox Pharmaceutical Corporation (Bahamas) - ADR.

        Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

        The CEO & director of Dr. Paul Averback DABP, M.D.. is Nymox Pharmaceutical Corporation (Bahamas) - ADR, and CFO & Sr. VP is Mr. Randall J. Lanham Esq., J.D..

        The promoters of Nymox Pharmaceutical Corporation (Bahamas) - ADR have pledged 0% of the total equity as on Jun-23.

        Some of the close peers are:

        Company Market Cap($ Mln)
        Nymox Pharmaceutical Corporation (Bahamas) - ADR Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Nymox Pharmaceutical Corporation (Bahamas) - ADR was $-1 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $18.25 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-1.49 Mln
        • Cash date-information $0.13 Mln
        • Total Debt info $0.81 Mln
        • Insider's Holding 45.03%
        • Liquidity liquidity Low
        • 52 Week range week-range $0.12 - 1.15
        • Shares outstanding share-outstanding 91,265,104
        • 10 Years Aggregate:

          CFO: $-66.99 Mln

          EBITDA: $-106.47 Mln

          Net Profit: $-108.66 Mln

        About The Company

        • IPO Date 01-Dec-1997
        • Founder, Chairman, CEO & Pres Dr. Paul Averback DABP, M.D.
        • Gen. Counsel, Sec., COO & Director Mr. Randall J. Lanham Esq., J.D.
        • Listing key-listing NASDAQ: NYMX
        • Country Bahamas
        • Headquarters headquarters Nassau
        • Website website https://nymox.com
        • Business

          Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate...  (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.  Read more

        share-fund-plan-icon